Venetoclax for elderly AML patients

Venetoclax for elderly AML patients

User Photo
VJHemOnc

2 years
289 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The BCL2 inhibitor venetoclax has shown remarkable response rates in elderly acute myeloid leukemia (AML) patients when used in combination regimens. Speaking at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, discusses how this, along with allogenic transplantation, has changed the way in which elderly AML patients are now being treated.
Up Next Autoplay
User Photo